CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Tuesday reported a loss of $88.5 million in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.62. Losses, adjusted for restructuring costs, came to $1.58 per share.
The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.
The biopharmaceutical company posted revenue of $5.4 million in the period, beating Street forecasts. Eight analysts surveyed by Zacks expected $5 million.
For the year, the company reported that its loss widened to $267.3 million, or $5.49 per share. Revenue was reported as $5.4 million.
Sarepta Therapeutics shares have risen 13 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $31.11, more than doubling in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT
Keywords: Sarepta Therapeutics, Earnings Report